ICAM1 blockade improves ischemic muscle reperfusion in diabetic mice

Area of Science:

• Vascular Biology
• Diabetic Complications
• Ischemia Research

Background:

• Chronic Limb-Threatening Ischemia (CLTI), the advanced stage of Peripheral Artery Disease (PAD), carries a high risk of amputation and mortality.
• Mechanisms driving PAD progression to CLTI remain incompletely understood, particularly in diabetic patients.

Purpose of the Study:

• To investigate the mechanisms underlying PAD exacerbation to CLTI in diabetic mice.
• To compare hind limb ischemia recovery in diabetic (HFD STZ) versus non-diabetic mice.

Main Methods:

• Utilized three mouse models of diabetes, including high-fat diet and streptozotocin (HFD STZ) induction.
• Assessed hind limb ischemia recovery, angiogenesis, myogenesis, capillary functionality, and immune cell infiltration.
• Employed ICAM1-blocking antibodies to evaluate its role in microvascular dysfunction.

Main Results:

• Diabetic mice showed impaired capillary functionality, including reduced intercellular junctions and immune quiescence.
• Increased ICAM1 expression, IgG permeability, and macrophage infiltration were observed in diabetic mice post-ischemia.
• ICAM1 blockade reduced white blood cell velocity and macrophage infiltration but did not resolve myopathy.

Conclusions:

• Microvascular ICAM1 expression significantly impairs ischemic muscle reperfusion in diabetic mice.
• Improved blood flow post-ischemia in diabetic mice is linked to enhanced capillary functionality, not increased density.
• Myopathy may contribute to microangiopathy, suggesting complex underlying mechanisms.